Rothfuss Cristin has filed 17 insider transactions across 1 company since November 2024.
Most recent transaction: a tax payment of 974 shares of Sarepta Therapeutics, Inc. ($SRPT) on March 11, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 11, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 974 | $17.03 | 137,544.0000 | 100,237,000 | 0.70% | 0.00% |
| March 9, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 346 | $16.95 | 138,518.0000 | 100,237,000 | 0.25% | 0.00% |
| March 9, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 484 | $16.95 | 138,864.0000 | 100,237,000 | 0.35% | 0.00% |
| March 2, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 408 | $16.20 | 139,348.0000 | 100,237,000 | 0.29% | 0.00% |
| Nov. 28, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 229 | $21.12 | 139,756.0000 | 100,237,000 | 0.16% | 0.00% |
| Sept. 3, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | A | Common Stock | 25000 | $0.00 | 139,985.0000 | 107,875,000 | 21.74% | 0.02% |
| Sept. 3, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | A | Common Stock | 93875 | $0.00 | 114,985.0000 | 107,875,000 | 444.69% | 0.09% |
| March 10, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 491 | $100.13 | 12,834.0000 | 107,875,000 | 3.68% | 0.00% |
| March 10, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | A | Common Stock | 8276 | $0.00 | 21,110.0000 | 107,875,000 | 64.48% | 0.01% |
| March 10, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | A | Stock Options (right to buy) | 16644 | $0.00 | 16,644.0000 | 107,875,000 | 9999.99% | 0.02% |
| March 7, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 347 | $103.70 | 11,847.0000 | 107,875,000 | 2.85% | 0.00% |
| March 7, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 1131 | $103.70 | 12,194.0000 | 107,875,000 | 8.49% | 0.00% |
| March 4, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 296 | $101.34 | 13,325.0000 | 107,875,000 | 2.17% | 0.00% |
| March 4, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 288 | $101.34 | 13,037.0000 | 107,875,000 | 2.16% | 0.00% |
| March 3, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | F | Common Stock | 391 | $103.77 | 13,621.0000 | 107,875,000 | 2.79% | 0.00% |
| Nov. 26, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | A | Common Stock | 2000 | $0.00 | 13,817.0000 | 100,448,000 | 16.92% | 0.00% |
| Nov. 26, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rothfuss Cristin | EVP, General Counsel | A | Stock Option (right to buy) | 4000 | $0.00 | 4,000.0000 | 100,448,000 | 9999.99% | 0.00% |